MISSOULA, Montana, March 29, 2023 – Inimmune, a leading biotech company focused on the development of novel vaccine adjuvants, immunotherapies, and delivery systems, announced today that its Investigator, Omer Rasheed, Ph.D., will participate and present a poster (P087) at the upcoming ACSMEDI-EFMC Medicinal Chemistry Frontiers 2023 in Boston entitled “Development of Novel STING Agonists as Vaccine Adjuvants” on Sunday, June 11 from 04:45- 06:00pm.
Stimulator of Interferon genes (STING) plays a central role in shaping both the innate and the adaptive immune response to microbial pathogens primarily by inducing the production of type I interferons (IFNs). STING-mediated processes therefore promote both antibody and cytotoxic T lymphocyte (CTL) immune responses against targeted antigens. Importantly, pharmacologic activation of STING-dependent phenotypes can be employed to greatly enhance vaccine-associated protective immunogenicity against viral, bacterial, and protozoal pathogens. These qualities have raised our interest in developing small molecule agonists of the STING pathway that can be used as adjuvants with protein-based vaccines.
Dr. Rasheed will be presenting the recent discovery of a novel series of non-nucleotide STING agonists that can be developed into adjuvants for vaccines against Zika and Chikungunya viruses. Dr. Rasheed’s poster can be viewed by clicking here.
EFMC-ACS Chemistry Frontiers 2023 is a 4-day international symposium devoted to the latest advances in drug discovery and development, medicinal and synthetic chemistry.
